상세 보기
Glofitamab Plus Gemcitabine and Oxaliplatin vs Rituximab Plus GemOx in Patients With Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Outcomes From the 3-Year Follow-Up of STARGLO
- Abramson, Jeremy S.;
- Ku, Matthew;
- Fox, Christopher P.;
- Huang, Hui-Qiang;
- Zhang, Huilai;
- ... Kim, Won-Seog;
- 외 14명
Citations
WEB OF SCIENCE
0키워드
ABCL; aggressive B-cell lymphoma; diffuse large B-cell lymphoma; relapsed/refractory; transplant-ineligible; bispecific antibodies; phase 3
- 제목
- Glofitamab Plus Gemcitabine and Oxaliplatin vs Rituximab Plus GemOx in Patients With Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Outcomes From the 3-Year Follow-Up of STARGLO
- 저자
- Abramson, Jeremy S.; Ku, Matthew; Fox, Christopher P.; Huang, Hui-Qiang; Zhang, Huilai; Townsend, William; Yoon, Dok Hyun; Kim, Won-Seog; Abdulhaq, Haifaa; Herbaux, Charles; Zaucha, Jan M.; Chang, Hung; Mulvihill, Estefania; Kesavan, Murali; Kallemeijn, Martine; Ta, Richard; Choeurng, Voleak; Bottos, Alessia; Lundberg, Linda; Gregory, Gareth P.
- 발행일
- 2026-08
- 유형
- Meeting Abstract
- 권
- 26
- 페이지
- S905 ~ S906
- 언어
- ENG
- 출판사
- ELSEVIER SCIENCE INC
- 발행국가
- 미국
- ISSN
- E 2152-2669
P 2152-2650